<DOC>
	<DOCNO>NCT00636064</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety parecoxib/valdecoxib therapy placebo/valdecoxib therapy treatment pain coronary artery bypass surgery</brief_summary>
	<brief_title>A Study Comparing Efficacy Safety Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo Treatment Pain After Coronary Artery Bypass Surgery</brief_title>
	<detailed_description />
	<mesh_term>Valdecoxib</mesh_term>
	<mesh_term>Parecoxib</mesh_term>
	<criteria>Inclusion criterion : Patients expect receive inhospital pain medication pain coronary artery bypass graft surgery least 3 full day pain medication 10day period New York Heart Association Class I III cardiac ejection fraction least 35 % surgery Body mass index less equal 40 kg/m2 weight &gt; 55 kg Patients schedule undergo isolate ( bypass graft without valve replacement , significant aortic reconstruction , ventriculoplasty ) primary CABG surgery via median sternotomy , use cardiopulmonary bypass Exclusion criterion : Patient undergone go emergency coronary artery bypass graft surgery surgery without cardiopulmonary bypass procedure Symptomatic peripheral vascular disease Heart attack within 48 hour surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>